|IAS 2016 St. Petersburg, Russia|
last updated: June 22, 2016
| FROM THE IAS PRESIDENT'S DESK |
IAS Consensus Statement “Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel”|
The International Atherosclerosis Society (IAS) is proud to announce the publication on the definition of severe FH and the implications for clinical management in The Lancet Diabetes and Endocrinology. The IAS Severe FH Panel, made of 25 internationally renowned experts and chaired by Dr. Raul Santos, worked with the objective of characterizing the severe FH phenotype and made recommendations on how to stratify CVD risk and to whom to prescribe the novel lipid lowering treatments. These recommendations will contribute to improved daily clinical practice and better management of FH patients.
To download the full text, which is open access, please link to and register at http://dx.doi.org/10.1016/S2213-8587(16)30041-9 (Published online May 27, 2016). For more information about
The Lancet, please visit The Lancet Homepage at www.thelancet.com.
IAS Visiting Fellowship Opportunities - Application Deadline is January 31, 2017|
For more information click here
- 3-Month Visiting Fellowship Award $5,000
- 6-Month Visiting fellowship Award $8,000
This website is a valuable source of information for the IAS members and the cardiovascular community. We draw your attention to the following featured connections. These are also listed (among others) in the left panel and include the following:
GUIDELINES A compilation of the guidelines on the prevention of atherosclerotic diseases published by several scientific Societies. These guidelines are readily available in pdf format or Power Point slides.
New additions: please check the latest guidelines: Brazilian FH guidelines.
CLINICAL TRIALS Abstracts of newly published clinical trials on atherosclerosis and the links to Pub Med, divided by topics and regularly updated. At the bottom of each trial abstract you will find a box where you can write your comments. Please limit your text to max 200 words. Your comments are encouraged.
E-NEWSLETTER AND E-LITERATURE The E-Newsletter provides a monthly update of the major activities of the IAS. The E-Literature lists the major articles published in the world's literature pertaining to atherosclerosis. It is a treasure trove of new scientific information.
SLIDES The IAS provides slides obtained from previous IAS meetings and co-sponsored meetings. It also links to the slide collection of the Lorenzini Foundation and other organizations that make slides available over the internet.
LINKS The website links to a very large number of organizations and government agencies in fields related to atherosclerosis and cardiovascular medicine. It further links to key databases, libraries and journals.
VIEW RECENT PAPERS ON ATHEROSCLEROSIS BY COUNTRY Finally, the website includes all recent publications in the atherosclerosis field from each country represented by our member societies. Visit the Member Societies Page (see right panel) and click on the country of your choice.
To view complete meeting schedule, please click here
| Upcoming Member Society Activities |
To view Endorsement guidelines and procedures, please click here
| Nonmember IAS Endorsed Activities |
To view all highlights, please click here
| Meeting and Educational Activity Highlights |
The IAS wishes to thank all the supporters which have generously offered grants to the IAS for the development of its many activities and in support of its mission during 2015:|
Aegerion Pharmaceuticals, Amgen, Inc., Amgen (Europe) GmbH, Daiichi Sankyo Co., Ltd., Fondazione Giovanni Lorenzini, OSLA - Oman Society of Lipids and Atherosclerosis, Otsuka Pharmaceutical Co., Ltd.,Pfizer, Sanofi and Regeneron, and Weill Cornell Medical College
This site is optimised for a min. 1024 x 768 pixels resolution
|IAS Newsletter Editors & Website Editorial Board|
Scott M. Grundy, MD, PhD
Dallas, TX, USA
Houston, TX, USA
Commentary & Newsletter Editor
(Dallas, TX, USA)